ArticleBMC cancer2026
Pan-cancer atlas of ITGA6 unveils its multifaceted oncogenic roles and therapeutic potential in uveal melanoma.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundIntegrin alpha 6 (ITGA6) has been implicated in tumorigenesis and progression, but its roles across cancer types and its functional significance in uveal melanoma (UVM) remain incompletely characterized.
methodsWe performed an integrated pan-cancer analysis of ITGA6 expression, diagnostic performance, prognostic relevance, immune associations, pathway activity, and drug sensitivity. In addition, we evaluated its functional role in UVM using in vitro assays, including proliferation, migration, invasion, and colony formation experiments following ITGA6 knockdown.
resultsITGA6 was upregulated in multiple tumor types, including lung squamous cell carcinoma and hepatocellular carcinoma. Diagnostic analysis indicated strong discriminatory value in several cancers, with AUC values > 0.95 in pheochromocytoma/paraganglioma and cholangiocarcinoma, and AUC values of 0.85-0.95 in pancreatic adenocarcinoma, hepatocellular carcinoma, kidney chromophobe, and head and neck squamous cell carcinoma. Survival analyses revealed that the prognostic association of ITGA6 was cancer-type dependent: higher ITGA6 expression correlated with better outcomes in skin cutaneous melanoma and uterine corpus endometrial carcinoma, but with worse outcomes in lung adenocarcinoma, lower-grade glioma, and UVM. In UVM, elevated ITGA6 expression was associated with poorer overall survival, progression-free interval, and disease-specific survival, and was positively correlated with immune infiltration and malignant functional states. ITGA6 expression showed positive correlations with all 14 functional state gene sets in UVM, with particularly strong correlations for angiogenesis, proliferation, and stemness. Pathway analyses further suggested that high ITGA6 expression was associated with epithelial-mesenchymal transition and TNF-α/NF-κB signaling. Drug sensitivity analyses identified several compounds that may be associated with ITGA6-related transcriptional signatures. Functional experiments showed that ITGA6 knockdown significantly inhibited proliferation, migration, invasion, and colony formation in UVM cells.
conclusionsThese findings suggest that ITGA6 may serve as a potential diagnostic and prognostic biomarker in selected cancers and support a tumor-promoting role for ITGA6 in UVM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.